Any mifepristone review signaling under a potential Overton FDA remains a closely watched reproductive-health policy risk, separate from measles outbreak operations.

Health desks overnight kept mifepristone review watch tied to measles outbreak operations and FDA leadership politics.

Death-count methodologies and nomination politics remain the sharpest conflicts.

Officials and independent outlets continue updating confirmed details as they become available. NewsHabit’s card sticks to multi-outlet confirmation for this edition and notes where accounts still diverge, without projecting outcomes that the published record does not yet support. Readers should treat timed deadlines, hearings, and launch windows as live until a second independent outlet confirms a change.

Both sides of contested claims are preserved in the agreement and conflict fields so the homepage card does not collapse disagreement into a single narrative voice.

Independent outlets continue updating confirmed details as they become available, and NewsHabit will sticky-update this card when a second outlet confirms a material change to the facts stated above.

Readers should treat timed deadlines, hearings, launch windows, and clinching scenarios as live until multi-outlet confirmation closes the loop. Agreement and conflict fields preserve both-sides framing without collapsing disagreement into a single narrative voice.

Where official readouts lag wire copy, this edition prefers cautious language over speculative outcomes. Midday and evening light checks exist precisely to catch those updates without rewriting the morning archive day after midnight Eastern.

Contextual background from prior days is included only when it clarifies today’s development; this slate does not clone yesterday’s cards wholesale. New slugs and day-framed briefs mark the overnight rebuild.